By Deena Beasley (Reuters) -Adding Amgen's cholesterol drug Repatha to standard therapy reduced major cardiovascular events ...

High cholesterol is a major driver of heart disease. Statins, like Lipitor and Zocor, emerged as powerful antidotes starting ...

A promising “two-in-one” experimental drug could tackle both type 2 diabetes and heart disease by slashing cholesterol and ...

While most people take their daily medications with trust, renowned US cardiologist Dr. Dimitry Yaranov has urged the public ...

Semaglutide, the active ingredient in Wegovy and Ozempic, lowers major cardiac event risk, regardless of how much weight a ...

Older adults face unique barriers in hypertension management, including comorbidities, mobility limitations, and medication adherence challenges, impacting digital health tool effectiveness. Trials ...

Prophylactic cardiac treatment in DMD patients is associated with a 54% lower hazard of death, highlighting its potential survival benefit. Only 27.7% of DMD patients received prophylactic cardiac ...

AstraZeneca beat expectations for third quarter earnings on Thursday with strong sales of its blockbuster cancer and ...

People with type 2 diabetes who combined healthy lifestyle habits with GLP-1 receptor agonist (GLP-1 RA) medications had a ...

MIT engineers have developed a flexible drug-delivery patch that can be placed on the heart after a heart attack to help ...

A preliminary study by the American Heart Association suggests that prolonged use of melatonin may be associated with a ...

Metoprolol, acebutolol, and propranolol are heart medications linked to weight gain. Other heart medications may cause weight gain, but some might cause weight loss or be weight neutral. Many ...